ClearBridge Investments
RYTM icon

ClearBridge Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

ClearBridge Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.3M Buy
696,473
+87,036
+14% +$7.87M 0.06% 261
2026
Q1 		$53M Buy
609,437
+103,328
+20% +$10M 0.05% 299
2025
Q4 		$54.2M Buy
506,109
+21,377
+4% +$2.27M 0.04% 313
2025
Q3 		$49M Buy
484,732
+172,287
+55% +$16M 0.04% 329
2025
Q2 		$19.7M Buy
+312,445
New +$19.1M 0.02% 418
2024
Q4 		– Sell
-87,424
Closed -$4.58M – 741
2024
Q3 		$4.58M Sell
87,424
-684
-0.8% -$32.8K ﹤0.01% 583
2024
Q2 		$3.62M Sell
88,108
-1,896
-2% -$75.7K ﹤0.01% 602
2024
Q1 		$3.9M Sell
90,004
-1,154
-1% -$50.5K ﹤0.01% 598
2023
Q4 		$4.19M Sell
91,158
-91,667
-50% -$2.89M ﹤0.01% 594
2023
Q3 		$4.19M Buy
+182,825
New +$4.09M ﹤0.01% 553
2020
Q3 		– Sell
-724
Closed -$16K – 952
2020
Q2 		$16K Hold
724
– – ﹤0.01% 863
2020
Q1 		$11K Sell
724
-24
-3% -$430 ﹤0.01% 941
2019
Q4 		$17K Hold
748
– – ﹤0.01% 973
2019
Q3 		$16K Sell
748
-30,047
-98% -$645K ﹤0.01% 961
2019
Q2 		$677K Hold
30,795
– – ﹤0.01% 680
2019
Q1 		$844K Buy
30,795
+3
+0% +$86 ﹤0.01% 687
2018
Q4 		$828K Sell
30,792
-15
-0% -$415 ﹤0.01% 700
2018
Q3 		$899K Sell
30,807
-47
-0.2% -$1.49K ﹤0.01% 732
2018
Q2 		$964K Sell
30,854
-7,410
-19% -$203K ﹤0.01% 650
2018
Q1 		$761K Buy
38,264
+36,476
+2,040% +$968K ﹤0.01% 653
2017
Q4 		$52K Buy
+1,788
New +$47.3K ﹤0.01% 845

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments's RYTM Position: Q2 2026 in Review

ClearBridge Investments increased its Rhythm Pharmaceuticals (RYTM) stake by 14% in Q2 2026, buying an estimated $7.87M and bringing the position to 696,473 shares worth $77.3M. The position accounts for 0.06% of the portfolio, ranked #261.

ClearBridge Investments first reported a position in RYTM in Q4 2017 and has held it in 21 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • ClearBridge Investments held 696,473 shares of Rhythm Pharmaceuticals worth $77.3M as of Q2 2026.
  • ClearBridge Investments bought 87,036 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $7.87M.
  • Rhythm Pharmaceuticals made up 0.06% of ClearBridge Investments's portfolio in Q2 2026, its #261 holding.
  • ClearBridge Investments first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 21 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.